|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||5.88 - 6.07|
|52 Week Range||4.83 - 7.00|
|Beta (3Y Monthly)||0.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shareholders have seen the share price descend 10% over the month. On the bright side the share price is up over the last half decade. In that time, it is up 31%, which...
NASHVILLE, Tenn., March 29, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced that it has commenced a strategic review of its branded product portfolio, as well as its roster of international partners. The Company expects to communicate results from the review during its upcoming report on the first quarter of 2019. Following the Company's acquisition of Vibativ® in late 2018, its commercial portfolio now includes eight FDA-approved brands.
Warning! GuruFocus has detected 3 Warning Signs with CPIX. For the last quarter Cumberland Pharmaceuticals Inc reported a revenue of $13.5 million, compared with the revenue of $11.65 million during the same period a year ago. For the last five years Cumberland Pharmaceuticals Inc had an average revenue growth rate of 4.4% a year.
A. Kazimi has been the CEO of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) since 1999. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. ThenRead More...
- Acquired Vibativ® from Theravance Biopharma - Closed largest product transaction in Company's history - Acquisition funded by $20 million credit line expansion NASHVILLE, Tenn. , Feb. 26, 2019 /PRNewswire/ ...
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, ...
NASHVILLE, Tenn. , Feb. 19, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2018 financial results after the market closes ...
As the CEO of Cumberland Pharmaceuticals, A.J. Kazimi runs one of the few drug companies in Nashville’s $46.7 billion health care industry. Under his leadership, Cumberland has partnered with Vanderbilt University, Louisiana State University, University of Mississippi and the University of Tennessee Research Foundation to help develop specialty products to add to the company’s growing portfolio.
Looking long term, the company says, it cuts 49 jobs as it pushes multiple programs deeper into clinical trials.
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is a small-cap stock with a market capitalization of US$96m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
Cumberland (CPIX) delivered earnings and revenue surprises of 73.68% and -7.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs and stock option expense, were 5 cents per share. The pharmaceutical ...
NASHVILLE, Tenn. , Nov. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive ...
NASHVILLE, Tenn. , Nov. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2018 financial results after the market closes on Tuesday, ...
VIBATIV is typically used in hospital settings for serious bacterial infections such as MRSA, pneumonia and skin infections.
DUBLIN, Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV® (telavancin), to Cumberland Pharmaceuticals, Inc. (CPIX), a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Under the terms of the agreement, Cumberland will pay Theravance Biopharma a total of $25 million and tiered royalties of up to 20% on future US net product sales. VIBATIV is a once-daily, injectable lipoglycopeptide antibiotic approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable.
NASHVILLE, Tenn., Nov. 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) announced today that it has entered into a definitive agreement to acquire VIBATIV® from Theravance Biopharma. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Theravance Biopharma, Inc. is a diversified pharmaceutical organization with the core purpose of helping improve the lives of patients suffering from serious illness.
Every investor in Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend Read More...